🔗 Share this article

A shadow economy for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on recent findings.

Experimental Drug Acquiring Popularity Via Social Media

Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its supposed weight-reducing effects. Viewers are urged to contact these accounts directly for supplier links, while also receiving promotional offers.

Active Commerce on Social Networks

Separately, a flourishing trade exists on messaging services, where communities with thousands of participants share “before and after” photos, injection guides and assertions of rapid UK delivery. Sellers market the drug there before directing customers to WhatsApp for transactions.

Learning About The Experimental Drug

This medication is an experimental injection developed by American pharmaceutical company Eli Lilly. The drug targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could help individuals reduce up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being hailed digitally as the next Ozempic.

Medical Professionals Express Concerns

Nevertheless, physicians and chemists have warned that the sale of what is still an unapproved medication in the UK is a cause for concern and could lead to individuals injecting products of unknown origin.

Some professionals stated the demand for the experimental drug could be connected to the rising price of approved slimming treatments such as Mounjaro.

Legal Status and Enforcement

Selling retatrutide on social media or messaging apps is prohibited in the UK, as it is an unlicensed drug that cannot be promoted or distributed for personal consumption under the British medical regulations.

Several content creators try to sidestep the regulations by calling to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but advertising and distribution can still violate medicines, advertising, and customer regulations, risking fines, prosecution or imprisonment.

Platform Reaction and Material Elimination

According to TikTok, the service has removed violative material and prohibited related keywords and search suggestions. The company stated it was committed to keeping the service safe and investing in strengthening compliance measures.

Digital Trading Activities

Investigations also discovered communities with up to nine thousand participants marketing the experimental drug using Telegram's integrated discovery tool, which functions like a public directory. Typing “retatrutide” instantly displays groups with numerous of users, filled with images of slimming results, positive testimonials and step-by-step instructions for preparing or injecting at home.

After minutes of entering one group, a vendor posted contact information, where most purchases take place. The vendor provided an instruction manual and promised delivery within two days. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a supposed testing documentation. Not one inquired about body mass, health issues or previous experience.

Item Information and Costs

Inside these communities, posts show black plastic packages with postal service stickers, stating to include fresh supplies. One message stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, mixed at residence with purified liquid, or pre-filled injectors typically priced at £160 for 20 milligrams. When questioned how much time a injector should be used, sellers give conflicting answers ranging from a few weeks to “depends on your body”.

Service Moderation and Security Actions

A representative for the messaging service said it actively moderated harmful content on its platform including material that encouraged the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Cautions

“People are administering substances they cannot confirm. Although the science behind this drug is valid, these online products may not contain what they claim,” stated Jason Murphy, the director of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor connected the increase in demand to recent price rises for authorized slimming drugs such as Mounjaro. “With costs increasing, patients are turning to social media. But counterfeit treatments are highly risky. You cannot know what’s inside or whether the conditions they were produced in was clean,” she explained.

Her team has already seen patients injured by personal administration from unconfirmed sources. “We recognize the frustration, but buying from messaging apps or communication platforms is gambling with your health,” said the doctor. “These substances could be impure or improperly measured.”

Manufacturer Statement

A representative from Eli Lilly said retatrutide was in phase 3 research studies and had not been reviewed or authorized by any government authority globally. “Consequently at this time no one can sell [it] for personal consumption,” they said, adding that any product “misleadingly claiming itself as a company experimental product not yet approved … may expose users to possibly serious health risks”.